ClinicalTrials.gg
CompletedNCT07424430SEMA-CKMUpdated Oct 13, 2026

Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes

An observational study in Diabetes (DM), Type 2 Diabetes and Obesity (Disorder), sponsored by LMC Diabetes & Endocrinology Ltd.. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by LMC Diabetes & Endocrinology Ltd. · Observational

How we know · 4 judgments

Updated Oct 13, 2026Now CompletedFirst site in Canada+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,392
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd. — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · LMC Diabetes & Endocrinology Ltd..

Started
2026
with 1 other
Observational
8 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd., this one is one of 2 that started in 2026, is one of 8 observational ones, and was the 13th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd., or all of them as a file.
02

Study summary

The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.

03

Conditions studied

  • Diabetes (DM)
  • Type 2 Diabetes
  • Obesity (Disorder)

Browse trials for

Keywords

  • semaglutide
  • T2D
  • AHA
  • HbA1c
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 3,392 is above the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

LMC Diabetes & Endocrinology Ltd. is the lead sponsor of 22 studies on the registry; 4 are open to participants now.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study populations will include adults with T2D prescribed semaglutide (T2D sema cohort) or other AHA (T2D other AHA cohort) including sulfonylurea, DPP4i, and/or SGLT2i, or adults with obesity, defined as BMI equal or greater 27 kg/m2, prescribed semaglutide (obesity sema cohort), who attend an LMC Diabetes \& Endocrinology clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

T2D Cohort:

  • A clinical diagnosis of T2D ≥ 1 year
  • ≥ 6.5% (pre-index date)
  • Initiated semaglutide or other AHA(s) before January 1st, 2023*
  • Seen by an LMC endocrinologist in the last 18 months as of the query date
  • ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date
  • Informed data consent for their medical record data to be used for research purposes

Obesity Cohort:

  • 18 years or older
  • ≥ 27 kg/m2
  • HbA1c \< 6.5% (pre-index date)
  • Initiated semaglutide before January 1st, 2023*
  • Seen by an LMC endocrinologist in the last 18 months as of the query date
  • ≥ one HbA1c value up to 6 months (± 90 days) prior to index date
  • Informed data consent for their medical record data to be used for research purposes

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of type 1 diabetes/latent diabetes in adults (LADA)
  • Clinical diagnosis of T2D (obesity cohort only)
  • Are pregnant at the time of semaglutide or other AHA initiation or became pregnant during follow-up period
  • Documented history or family history of medullary thyroid carcinoma
  • Participation in a research study with an Product
  • \< 15 mL/min/1.73m2 at index date
  • Use of non-semaglutide GLP-1-based medication for more than 6 months after the index date (T2D sema cohort and obesity sema cohort)
  • Use of other AHA for more than 6 months after the index date within the first year of semaglutide use (T2D sema cohort and obesity sema cohort)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,392 participants (actual)
Patient registry
No

Groups and cohorts

  • T2D Semaglutide Cohort

    Adults with T2D prescribed semaglutide

    Drug: Semaglutide (SEMA)

  • T2D other AHA cohort

    Adults with T2D prescribed antihyperglycemic medication beside semaglutide including sulfonylurea, DPP4i, and/or SGLT2i

  • Obesity Semaglutide Cohort

    Adults with obesity, defined as BMI equal or greater than 27 kg/m2, prescribed semaglutide

    Drug: Semaglutide (SEMA)

Interventions

07

What researchers measure

Primary outcomes

  1. Change in HbA1c- 3 Years

    The primary outcome measure is investigating the change in HbA1c from baseline to 3 years (± 90 days) among adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs

    Time frame: Baseline to 3 Years

Secondary outcomes

  1. Change in HbA1c- 1 Year

    Comparing the change in HbA1c between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 year

  2. Change in HbA1c- 2 Years

    Comparing the change in HbA1c between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  3. Proportion of individuals who achieve HbA1c ≤ 7.0% - 1 Year

    comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  4. Proportion of individuals who achieve HbA1c ≤ 7.0%- 2 Years

    comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  5. Proportion of individuals who achieve HbA1c ≤ 7.0% - 3 Years

    comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  6. Change in body weight- 1 Year

    comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  7. Change in body weight- 2 Years

    comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  8. Change in body weight- 3 Years

    comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  9. Percent body weight loss ≥ 5% - 1 Year

    comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  10. Percent body weight loss ≥ 5% - 2 Years

    comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  11. Percent body weight loss ≥ 5% - 3 Years

    comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  12. Percent body weight loss ≥ 10% - 1 Year

    comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  13. Percent body weight loss ≥ 10% - 2 Years

    comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  14. Percent body weight loss ≥ 10% - 3 Years

    comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  15. Percent body weight loss ≥ 15% - 1 Year

    comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  16. Percent body weight loss ≥ 15%- 2 Years

    comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  17. Percent body weight loss ≥ 15%- 3 Years

    comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  18. Change in BMI- 1 Year

    comparing the change in BMI (kg/m\^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  19. Change in BMI- 2 Years

    comparing the change in BMI (kg/m\^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  20. Change in BMI- 3 Years

    comparing the change in BMI (kg/m\^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  21. Change in Waist Circumference- 1 Year

    comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  22. Change in Waist Circumference- 2 Years

    comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  23. Change in Waist Circumference- 3 Years

    comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  24. Change in Blood Pressure- 1 Year

    comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  25. Change in Blood Pressure- 2 Years

    comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  26. Change in Blood Pressure- 3 Years

    comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  27. Change in eGFR- 1 Year

    comparing the change in eGFR (ml/min1.73m\^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  28. Change in eGFR- 2 Years

    comparing the change in eGFR (ml/min1.73m\^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  29. Change in eGFR- 3 Years

    comparing the change in eGFR (ml/min1.73m\^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  30. Proportion of individuals with ≥ 50% decline in eGFR- 1 Year

    comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  31. Proportion of individuals with ≥ 50% decline in eGFR- 2 Years

    comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  32. Proportion of individuals with ≥ 50% decline in eGFR- 3 Years

    comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  33. Change in uACR- 1 year

    comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  34. Change in uACR- 2 years

    comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  35. Change in uACR- 3 Years

    comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  36. Change in ALT- 1 Year

    comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  37. Change in ALT- 2 Years

    comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  38. Change in ALT- 3 Years

    comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  39. Change in Lipids- 1 Year

    comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol \[LDL-C\], high-density lipoprotein cholesterol \[HDL-C\], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  40. Change in Lipids- 2 Years

    comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol \[LDL-C\], high-density lipoprotein cholesterol \[HDL-C\], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  41. Change in Lipids- 3 Years

    comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol \[LDL-C\], high-density lipoprotein cholesterol \[HDL-C\], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  42. Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 1 Year

    comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  43. Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 2 Years

    comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  44. Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 3 Years

    comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  45. Number of non-semaglutide GLP-1-based therapies- 1 Year

    comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  46. Number of non-semaglutide GLP-1-based therapies- 2 Years

    comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  47. Number of non-semaglutide GLP-1-based therapies- 3 Years

    comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  48. Change in insulin use- 1 Year

    comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  49. Change in Insulin- 2 Years

    comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  50. Change in Insulin- 3 Years

    comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  51. Change in TDD of insulin- 1 Year

    comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 1 Year

  52. Change in TDD of insulin- 2 Years

    comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 2 Years

  53. Change in TDD of insulin- 3 Years

    comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts

    Time frame: Baseline to 3 Years

  54. Incidence of non-acetylsalicylic acid antiplatelet use

    comparing the incidence of non-acetylsalicylic acid antiplatelet use between adults with T2D treated with 1 or more years of semaglutide and adults with T2D treated with 1 or more years of other AHAs in the cardiovascular sub-cohort

    Time frame: Baseline to Endpoint

  55. Percent body weight loss ≥ 5%

    Comparing the percent body weight loss ≥ 5% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 Year

  56. Percent body weight loss ≥ 10%

    Comparing the percent body weight loss ≥ 10% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 Year

  57. Percent body weight loss ≥ 15%

    Comparing the percent body weight loss ≥ 15% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 Year

  58. Body Weight

    Comparing body weight (kg) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 Year

  59. BMI

    Comparing BMI (km/m\^2) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 Year

  60. Waist Circumference

    Comparing the waist circumference (cm) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 Year

  61. HbA1c

    Comparing HbA1c (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 Year

  62. Percent of new onset pre-diabetes

    Comparing the percent of new onset pre-diabetes (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 Year

  63. Percent of new onset T2D

    Comparing the percent of new onset T2D (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 Year

  64. Blood Pressure

    Comparing blood pressure in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 Year

  65. eGFR

    Comparing eGFR (ml/min1.73m\^2) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 year

  66. uACR

    Comparing uACR (mg/mmol) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 Year

  67. ALT

    Comparing ALT (U/L) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 Year

  68. Lipids

    Comparing lipids (triglycerides, LDL-C, HDL-C , total cholesterol) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)

    Time frame: Baseline to 1 Year

Other outcomes

  1. HbA1c

    Comparing HbA1c between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

    Time frame: Baseline to Endpoint (3 Years)

  2. Proportion of individuals who achieve HbA1c ≤ 7.0%

    Comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

    Time frame: Baseline to Endpoint (3 Years)

  3. Body Weight

    Comparing body weight (kg) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

    Time frame: Baseline to Endpoint (3 Years)

  4. Percent body weight loss ≥ 5%

    Comparing percent body weight loss ≥ 5% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

    Time frame: Baseline to Endpoint (3 Years)

  5. Percent body weight loss ≥ 10%

    Comparing percent body weight loss ≥ 10% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

    Time frame: Baseline to Endpoint (3 Years)

  6. Percent body weight loss ≥ 15%

    Comparing percent body weight loss ≥ 15% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

    Time frame: Baseline to Endpoint (3 Years)

  7. BMI

    Comparing BMI (kg/m\^2) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

    Time frame: Baseline to Endpoint (3 Years)

  8. eGFR

    Comparing eGFR (ml/min1.73m\^2) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

    Time frame: Baseline to Endpoint (3 Years)

  9. Proportion of individuals with ≥ 50% decline in eGFR

    Comparing the proportion of individuals with ≥ 50% decline in eGFR between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

    Time frame: Baseline to Endpoint (3 Years)

  10. uACR

    Comparing uACR (mg/mmol) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

    Time frame: Baseline to Endpoint (3 Years)

  11. ALT

    Comparing ALT (U/L) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups

    Time frame: Baseline to Endpoint (3 Years)

08

Study locations

1 site
  • LMC Diabetes & Endocrinology Ltd.
    Toronto, Ontario M4G 3E8, Canada
09

References and documents

Individual participant data

Plan to share: No — This is an observational study using data retrieved from a national diabetes registry. IPD will not be shared.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2026 to primary completion in Sep 2026, 7 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Mar 2026 → Feb 2026, primary completion Apr 2026 → Sep 2026 and completion May 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Feb 20, 2026
StartActual
Feb 20, 2026was Mar 2026
Primary completionActual
Sep 28, 2026was Apr 2026
CompletionActual
Sep 28, 2026was May 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 13, 2026
Sites
1 site added — first site in Canada
Show site
  • LMC Diabetes & Endocrinology Ltd. · Toronto, Canada
Oct 13, 2026
Start date
Mar 2026→Feb 20, 2026 (actual)
Oct 13, 2026
Primary completion
Apr 2026→Sep 28, 2026 (actual)
Oct 13, 2026
Study completion
May 2026→Sep 28, 2026 (actual)
Oct 13, 2026
Enrollment
400 (estimated)→3392 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Completed
    1 site added — first site in Canada
    Show site
    • LMC Diabetes & Endocrinology Ltd. · Toronto, Canada
    Start date Mar 2026→Feb 20, 2026 (now actual)
    Primary completion Apr 2026→Sep 28, 2026 (now actual)
    Study completion May 2026→Sep 28, 2026 (now actual)
    Enrollment 400 (estimated)→3392 (actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07424430
Lead sponsor
LMC Diabetes & Endocrinology Ltd.
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Feb 20, 2026
Primary completion
Sep 28, 2026
Completion
Sep 28, 2026
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion